Investment bank Leerink Partners recently released a research report, initiating coverage on biotechnology company Satellos Bioscience Inc. (stock symbol: MSLE) for the first time.

The institution has given the company a positive “Outperform” rating and set a target share price of $20. This rating reflects analysts’ optimistic outlook on the future development prospects of Satellos Bioscience. As a biotechnology company focused on the development of innovative therapies, Satellos Bioscience has attracted market attention with its unique technology platform. Coverage by Leerink Partners will provide investors with professional research references.